General Archive
-
Funding: CF AMR Syndicate funding call for new cystic fibrosis therapies
Funding: CF AMR Syndicate funding call for new cystic fibrosis therapies LifeArc, as part of the CF AMR Syndicate, is…
-
Funding: Drug repurposing call to treat chronic respiratory infection
Funding: Drug repurposing call to treat chronic respiratory infection LifeArc has committed £10m to fund up to five consortia programmes…
-
News releases
LifeArc’s Edinburgh labs featured in STV segment about innovations for people living with bronchiectasis
Recently, our team had the pleasure of hosting STV for an exciting feature at the BioQuarter campus in Edinburgh. Watch…
-
News releases
NHS trial uses artificial intelligence to predict severe infections and transform lives of people living with chronic lung conditions
A new NHS trial is using a home monitoring app combined with artificial intelligence (AI) to predict when people living…
-
News releases
LifeArc & Cystic Fibrosis Trust announce new £15m research funding to fast track treatment of lung infections
Focussing on innovative approaches to improve quality of life for people with cystic fibrosis (CF)
-
News releases
LifeArc plans two major funding calls to boost translational research in rare disease & lung health in cystic fibrosis
The calls are part of our wider £100m programme to support scientific innovation for people living with cystic fibrosis.
-
News releases
£3m fund to accelerate development of new CF therapies
Collaborative funding to drug discovery innovators to accelerate new treatments for people with cystic fibrosis.
-
News releases
LifeArc partners with EMBARC to improve healthcare for people living with bronchiectasis
Three-year partnership to improve healthcare for thousands of people across Europe living with bronchiectasis.
-
News releases
LifeArc announces £10m funding call for new chronic respiratory infection therapies
First major funding call announced as part of our £100m Chronic Respiratory Infection Translational Challenge
-
News releases
£100m programme to transform care for people living with chronic lung conditions
More than 300,000 people in the UK are living with bronchiectasis and more than 10,000 have been diagnosed with cystic…
-
News releases
LifeArc funds home monitoring trials for people with chronic respiratory conditions
Trials will examine the impact of home monitoring and machine learning decision support algorithms for people with CF and bronchiectasis.
-
Articles & blogs, Ventures funding
AbbVie acquires LifeArc portfolio company DJS Antibodies
AbbVie will pay DJS shareholders approximately $255 million in cash at closing for the acquisition of DJS